Linklaters Advises Jacobs Capital on Sale of Stingray Healthcare to Amethyst Radiotherapy

"Linklaters advised European investment firm Jacobs Capital on the sale of oncology services provider Stingray Healthcare to Amethyst Radiotherapy, a pan‑European radiotherapy group and portfolio company of Fremman Capital. Stingray operates cancer treatment centres across Europe, with core operations in Germany and France."

Linklaters advised European investment firm Jacobs Capital on the disposal of Stingray Healthcare to Amethyst Radiotherapy, a portfolio company of Fremman Capital. The transaction comprises the sale by Jacobs Capital of Stingray Healthcare to Amethyst Radiotherapy. Stingray Healthcare operates cancer treatment centres across Europe through partnerships with cancer care professionals, providing financial resources and strategic expertise, with core operations in Germany and France. Amethyst Radiotherapy is a pan‑European radiotherapy provider and is a portfolio company of Fremman Capital. Linklaters represented Jacobs Capital with a team composed by: Ben Rodham, Private Equity Partner; Martin Arnal, Managing Associate, Private Equity; Louisa Pratt, Associate, Private Equity; Jamie Coomber, Tax Partner; Thomas Waller, Leveraged Finance Partner; Neil Hoolihan, Antitrust Partner (Brussels); Karolis Pocius, Managing Associate (Antitrust, Brussels); Maxime Bertomeu‑Savalle, Corporate Counsel (Luxembourg); Aurélie Mounier, Managing Associate (Luxembourg).

Linklaters Advises Jacobs Capital on Sale of Stingray Healthcare to Amethyst Radiotherapy

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads